Tosoh Corporation

Link Genomics, Inc.

Science Farm Ltd.

Masami Otsuka

Takahiko Ishiguro

Yukio Sugiura

Teruhiko Inoue

Juichi Saitoh

Hideo Yawata

Lin Kurahara

Hironobu Ihn

The present invention provides a pharmaceutical composition for preventing and/or treating a disease characterized by fibrosis of a cell or a tissue, the pharmaceutical composition comprising a compound represented by formula 1 or a salt thereof, and a pharmaceutically acceptable carrier.

Fibrosis drug

A method of specifically cleaving a double-stranded DNA (a target nucleic acid) at a specific nucleic acid sequence, which comprises irradiating a solution containing at least the target nucleic acid, a nucleic acid probe (a single-stranded oligonucleotide) linked to an intercalater and spermine with light with an absorption wavelength of the intercalater.

Method of cleaving specific nucleic acid sequence

A labeled nucleic acid probe comprising a single-stranded oligonucleotide probe having a nucleic acid sequence complementary to a specific nucleic acid sequence in a target nucleic acid and an intercalating fluorochrome bound to said probe is used to detect the target nucleic acid by a convenient, single-stage method in a homogeneous system. The formation of a complementary bond between the probe and the target nucleic acid can be detected and the amount of the resulting complementary binding product determined without requiring any extra step such as for removing the excess probe which has not participated in the complementary binding.

Method of detecting specific nucleic acid sequences

Growing community of inventors

Kumamoto, Japan

Masami Otsuka